Digest Network Come funziona
Network
/
Società
AC
Non verificato

ACADIA Pharmaceuticals Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VariePsichiatriaSalute

84 comunicati stampa

Guarda tutti i comunicati
24/08/2026
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
04/08/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Psichiatria
Medicina - Varie
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
30/07/2026
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
20/07/2026
Industria
Psichiatria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
15/07/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Psichiatria
Sanità
Salute
Farmaceutica
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
06/07/2026
Psichiatria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
26/06/2026
Industria
Biotecnologia
Farmaceutica
Salute
Malattie rare – Dal CHMP parere positivo per trofinetide per il trattamento della sindrome di Rett
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
26/06/2026
Industria
Biotecnologia
Farmaceutica
Salute
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
06/05/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
Sanità
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
30/04/2026
Mercato del lavoro
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0